HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GMP Documentation, Identity Testing Continue To Trip Supplement Firms

This article was originally published in The Tan Sheet & The Rose Sheet

Executive Summary

Warnings from FDA's Office of Regulatory Affairs make clear that failing to document compliance with each GMP requirement renders those parts of the process noncompliant. Warning letters posted March 22 also include FDA's latest enforcement against firms marketing bulk caffeine.

You may also be interested in...



US DoJ Has Own Eyes On Consumer Health Fraud

Firms moving from noncompliance to compliance with FDA or FTC requirements still could hear from federal prosecutors. “Our office has grown to the point that we generate a fair amount of work ourselves,” says Patrick Runkle, a trial attorney in DoJ Consumer Protection Branch.

Own-Labeler Lesson, Ingredient-Testing Lapse Noted Again In FDA Warnings

Sportron International "cannot contract out its ultimate responsibility to ensure that the dietary supplement it places into commerce" is compliant, and Absonutrix failed "to conduct at least one appropriate test or examination to verify the identity of a dietary ingredient," say FDA warning letters listing some of the most frequently noted problems found in GMP and labeling inspections.

FDA Takes The Measure Of Bulk Caffeine In Warnings About Labels

Serving amounts such as one-sixteenth of a teaspoon indicated on product labels “cannot be accurately measured using common household measuring tools,” FDA says. NPA, however, suggests the agency gives too little credit to consumers’ measuring skills.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS123068

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel